Evidence map›Paper›PMID 25533764›Full record

ArticleNuclear medicine and biology2015

Detection of breast cancer microcalcification using (99m)Tc-MDP SPECT or Osteosense 750EX FMT imaging.

Dayo D Felix, John C Gore, Thomas E Yankeelov, Todd E Peterson, Stephanie Barnes, Jennifer Whisenant, Jared Weis, Sepideh Shoukouhi, John Virostko, Michael Nickels and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Dayo D FelixVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
John C GoreVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Physics Astronomy, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Biomedical Engineering, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Cancer Biology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Thomas E YankeelovVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Physics Astronomy, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Biomedical Engineering, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Molecular physiology and Biophysics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Todd E PetersonVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Physics Astronomy, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Stephanie BarnesVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Jennifer WhisenantVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Jared WeisVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Sepideh ShoukouhiVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
John VirostkoVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Michael NickelsVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
J Oliver McIntyreVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Molecular physiology and Biophysics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Melinda SandersDepartment of Pathology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Vandana AbramsonDepartment of Hematology/Oncology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA.
Mohammed N TantawyVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA. Electronic address: mohammed.n.tantawy@vanderblt.edu.
Vanderbilt University Medical Center · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
Vanderbilt In Vivo Cellular and Molecular Imaging CenterP50CA128323 · NCI · VANDERBILT UNIVERSITY · PI SHYR, YU · 2008 to 2012
$6.8M
Evaluation and Validation of Imaging Biomarkers of Tumor Response to TreatmentR01CA138599 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MCINTYRE, JAMES OLIVER · 2010 to 2015
$2.2M
NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA68485NCI NIH HHS P50 CA098131NCI NIH HHS P50CA098131NCI NIH HHS P50 CA128323NCI NIH HHS R01 CA138599NCI NIH HHS R01CA138599
6 · The paper itself

Abstract

backgroundIn previous work, we demonstrated the presence of hydroxyapetite (type II microcalcification), HAP, in triple negative MDA-MB-231 breast cancer cells. We used (18)F-NaF to detect these types of cancers in mouse models as the free fluorine, (18)F(-), binds to HAP similar to bone uptake. In this work, we investigate other bone targeting agents and techniques including (99m)Tc-MDP SPECT and Osteosense 750EX FMT imaging as alternatives for breast cancer diagnosis via targeting HAP within the tumor microenvironment.

methodsThirteen mice were injected subcutaneously in the right flank with 10(6) MDA-MB-231 cells. When the tumor size reached ~0.6 cm(3), mice (n=9) were injected with ~37 MBq of (99m)Tc-MDP intravenously and then imaged one hour later in a NanoSPECT/CT or injected intravenously with 4 nmol/g of Osetosense 750EX and imaged 24 hours later in an FMT (n=4). The imaging probe concentration in the tumor was compared to that of muscle. Following SPECT imaging, the tumors were harvested, sectioned into 10 μm slices, and underwent autoradiography or von Kossa staining to correlate (99m)Tc-MDP binding with HAP distribution within the tumor. The SPECT images were normalized to the injected dose and regions-of-interest (ROIs) were drawn around bone, tumor, and muscle to obtain the radiotracer concentration in these regions in units of percent injected dose per unit volume. ROIs were drawn around bone and tumor in the FMT images as no FMT signal was observed in normal muscle.

resultsUptake of (99m)Tc-MDP was observed in the bone and tumor with little or no uptake in the muscle with concentrations of 11.34±1.46 (mean±SD), 2.22±0.95, and 0.05±0.04%ID/cc, respectively. Uptake of Osteosense 750EX was also observed in the bone and tumor with concentrations of 0.35±0.07 (mean±SD) and 0.04±0.01picomoles, respectively. No FMT signal was observed in the normal muscle. There was no significant difference in the bone-to-tumor ratio between the two modalities (5.1±2.3 for SPECT and 8.8±2.2 for FMT) indicating that there is little difference in tumor uptake between these two agents.

conclusionThis study provides evidence of the accessibility of HAP within the breast tumor microenvironment as an in vivo imaging target for bone-seeking agents. SPECT imaging using (99m)Tc-MDP can be rapidly translated to the clinic. FMT imaging using Osteosense 750EX is not currently approved for clinical use and is limited to animal research.

Indexed as

Optical ImagingTechnetium Tc 99m MedronateTomography, Emission-Computed, Single-PhotonAnimalsBone and BonesBreast NeoplasmsCalcinosisCell Line, TumorHumansMiceTomography, X-Ray ComputedTechnetium Tc 99m Medronate(99m)Tc-MDPBreast cancerHydroxyapetiteMDA-MB-231MicrocalcificationSPECT

Identifiers

PMID25533764
PMCPMC4889014
OpenAlexW2072846564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.